Vibrant Therapeutics
Vibrant Therapeutics Raises $61M Series B | Logic-Gated Cancer Immunotherapy
Vibrant Therapeutics Closes $61M for Cancer Immunotherapy
Vibrant Therapeutics, developing logic-gated cancer immunotherapies that activate only in tumor microenvironments, has raised $61 million in Series B funding.
The round was co-led by Pfizer Ventures and Apricot Capital with participation from Bayland Capital and Northern Light Venture Capital.
Key Highlights
- Strategic backing from Pfizer Ventures
- Logic-gated immunotherapy platform
- Tumor microenvironment activation
Company Overview
Vibrant Therapeutics is pioneering logic-gated cancer immunotherapies designed to activate specifically in tumor microenvironments, potentially reducing systemic toxicity while enhancing anti-tumor efficacy.
Company Info
Investors (3)
Share
Related Reports
Armadin Raises $255.5M Series B for Autonomous Security
Armadin raised a $255.5 million Series B co-led by Andreessen Horowitz and Accel to scale its agentic security platform and its research, training, and go-to-market efforts.
Homeward Raises $120M Series D for Cash Offer and Bridge Financing
Homeward raised a $120 million Series D led by Saluda Grade, plus $330 million in asset-backed debt, to expand cash offer and bridge financing for real estate agents.
Varda Raises $251M Series D for Space-Based Pharmaceutical Processing
Varda Space Industries raised a $251 million Series D led by Lux Capital and Natural Capital to scale space-based pharmaceutical processing.
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free